The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15%

In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers.

London

Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings.

DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics.

To request a sample copy / brochure of this report, please visit link
https://www.rootsanalysis.com/....reports/dna-and-gene

Key Market Insights

Around 80 companies claim to offer DNA and gene cloning services, globally
Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers.

Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning
Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning.


Over 1,350 patents related to DNA and gene cloning in biopharmaceutical industry have been filed / granted since 2017
Owing to the increase in research and development efforts by various industry and non-industry players engaged in this domain, close to 60% of patent applications have been filed post-2018. It is worth noting that 57% patents related to DNA and gene cloning have been filed by non-industry players.

Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018
More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences.

Over 35 global events related to DNA and gene cloning have been organized since 2017
Majority of the events related to DNA and gene cloning were organized in Asia-Pacific (64%). It is worth highlighting that the agendas of the events organized post-2020 include discussions on the potential, advancements and challenges associated with DNA and gene cloning techniques.

For additional details, please visit
https://www.rootsanalysis.com/....reports/dna-and-gene
or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The human microbiome market is anticipated to grow at a CAGR of 24% till 2035

With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications.


Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings.

The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/281/request-

Key Market Insights

Over 230 drug candidates are currently being developed by more than 70 drug developers
Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders.


Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021
Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period.

More than USD 1 billion has been invested by both private and public investors, since 2017
Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million.

Outsourcing has become an integral part of the microbiome and live biotherapeutics development process
Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe.

Microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035
As late-stage therapeutics will get approved by the FDA in the foreseen future, the microbiome therapeutics market is likely to grow at an annualized rate of 37% till 2035. It is worth mentioning that microbiome diagnostics is likely to capture 20% of the total microbiome market share by 2035.

For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

Oral Proteins and Peptides Market

Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics.

Considering the therapeutic advantages associated with proteins and peptides, this field has witnessed significant activity; researchers are actively evaluating orally bioavailable interventions. However, owing to their inherently complex structure and comparatively low stability (in in vivo conditions), proteins / peptides are predominantly administered parenterally. Recent strides in drug delivery solutions have enabled scientists to successfully explore and exploit alternative routes of drug delivery, such as transdermal, intranasal, pulmonary and oral, for protein / peptide-based therapeutics. Of these, the oral route of delivery is considered to be the most patient-friendly. This has led several companies to invest in the development of orally administered biologics. The delivery of proteins and peptides utilizes the following routes of administration. Since the approval of the first protein / peptide-based therapy (recombinant human insulin) in 1982, there has been a substantial increase in the R&D initiatives focused on such products. Earlier, majority of the biologics were administered subcutaneously. However, with the technological advancements in delivery formulations, oral delivery of therapeutic interventions has gained significant traction, prompting stakeholders to leverage their expertise in the development of orally administrable proteins / peptides.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/192/request-


Although studies have reported that over XX oral drug delivery technologies have been designed so far, our research indicates that only XX% of the aforementioned technologies are currently being used to develop therapeutic proteins / peptides. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral proteins / peptide therapeutics market is anticipated to witness significant growth in the coming future.


For additional details, please visit https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035

An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries.

Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings.

Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/needlestick-

Key Market Insights

Currently, around 120 needlestick safety injection devices are available in the market
More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections.

Over 50 companies claim to develop needlestick safety injection devices, worldwide
Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%).

Partnership activity within this field has grown significantly between 2020 and 2022
Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions.

Over USD 260 million has been invested by both private and public investors, since 2016
Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain.

Close to 20 global events were organized in the past couple of years in this industry
Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries.

More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018
Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes.

For additional details, please visit https://www.rootsanalysis.com/....reports/needlestick- or email sales@rootsanalysis.com


You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Cell Therapy Manufacturing Market, 2021-2030
3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/compa....ny/roots-analysis/my
Twitter - https://twitter.com/RootsAnalysis
Medium - https://medium.com/@RootsAnalysis
Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
Quora - https://rootsanalysisinsights.quora.com/

APTAMERS: THERAPEUTICS, TECHNOLOGIES, AND SERVICES MARKET – THE RISING REALM AMONGST STAKEHOLDERS IN PURSUIT OF ALTERNATIVE THERAPIES TO ANTIBODIES THERAPIES

Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD).

It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America. This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for aptamers-based therapeutics and diagnostic solutions. Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis. To ensure the development of more effective aptamer-based therapies candidates, several players have developed novel aptamer technologies that can be used for research, drug delivery and diagnostic applications. At present, such technologies are widely being used for pathogen recognition, cancer recognition, monitoring environmental contamination, and as stem cell markers, which can help in both disease prevention and treatment.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/aptamers-the

Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process. Other noteworthy developments in modifications of aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance.

Steps involved in the SELEX process:
 Library Generation: Oligonucleotide library is created containing single-stranded nucleic acids having random sequences flanked by binding sites.
 Binding and Separation: Target molecule is incubated along with the oligonucleotide library allowing for nucleic acids to bind to them resulting in the formation of aptamers. The remaining unbound nucleic acids are filtered out of the solution and through the process of elution the bound nucleic acid is separated from the target.
 Amplification: The nucleic acids separated through the process of elution are then used to create a new library using the Polymerase Chain Reaction (PCR), this provides a new library that can be utilized for new round of SELEX thus, improving the quality of aptamers synthesized
ADVANTAGES OF APTAMERS
For many years, researchers have been raising and modifying antibodies to detect specific circulating proteins and develop targeted therapeutic agents. While antibodies are highly effective for a wide range of applications, there are unique aptamer advantages that can overcome some difficult scientific challenges.
 Targets small molecules: Flexibility of aptamers offer wider applications as they can be developed against molecules as small as 60 Daltons this means aptamers can target molecules that are ten times smaller than antibody targets. Currently, aptamers for small molecule drugs, peptides, dyes and viral particles have been developed successfully.


For additional details, please visit:- https://www.rootsanalysis.com/....reports/aptamers-the

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Gene Editing beyond CRISPR Market, 2022-2035
3. Cell and Gene Therapy Bioassay Services Market, 2021-2030

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis